Literature DB >> 23316799

Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes.

Ewa Wender-Ozegowska1, Agnieszka Zawiejska, Katarzyna Ozegowska, Katarzyna Wroblewska-Seniuk, Rafal Iciek, Urszula Mantaj, Danuta Olejniczak, Jacek Brazert.   

Abstract

AIMS: The aim was to evaluate the outcome of pregnancies with type 1 diabetes (T1DM) treated from the first trimester with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).
METHODS: In a retrospective, observational study, we matched 64 CSII patients for age, age at onset and duration of diabetes and HbA1c in the first trimester with 64 MDI pregnancies. We analysed carbohydrate metabolism, insulin requirements, development of PIH, progression of retinopathy and fetal outcome.
RESULTS: In CSII group, we found a significantly smaller insulin requirement both at the beginning of pregnancy and before delivery, significant decrease in HbA1c levels and significantly smaller number of hypoglycaemic episodes in the second trimester and significantly more hyperglycaemic episodes in the first trimester. In both groups, maternal, fetal and perinatal outcomes were similar and the number of hypo- and hyperglycaemic episodes decreased throughout pregnancy.
CONCLUSION: Continuous subcutaneous insulin infusion (CSII) treatment in pregnant women with type 1 diabetes is associated with a reduced number of hypoglycaemia and decreased insulin requirement. We noted no difference in perinatal outcome comparing women on multiple insulin injections with those on continuous insulin infusion.
© 2013 The Authors ANZJOG © 2013 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316799     DOI: 10.1111/ajo.12027

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  7 in total

Review 1.  Comparative effectiveness of continuous subcutaneous insulin infusion using insulin analogs and multiple daily injections in pregnant women with diabetes mellitus: a systematic review and meta-analysis.

Authors:  Padmini D Ranasinghe; Nisa M Maruthur; Wanda K Nicholson; Hsin-Chieh Yeh; Todd Brown; Yong Suh; Lisa M Wilson; Elisabeth B Nannes; Zack Berger; Eric B Bass; Sherita Hill Golden
Journal:  J Womens Health (Larchmt)       Date:  2015-02-25       Impact factor: 2.681

2.  Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes.

Authors:  Melissa M Kallas-Koeman; Jason M Kong; Jennifer A Klinke; Sonia Butalia; Abhay K Lodha; Ken I Lim; Qiuli M Duan; Lois E Donovan
Journal:  Diabetologia       Date:  2014-01-17       Impact factor: 10.122

3.  Pregnancy outcomes among women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion versus multiple daily injections: A retrospective cohort study.

Authors:  Benjamin Rs Dixon; Alison Nankervis; Stephanie Cn Hopkins; Thomas J Cade
Journal:  Obstet Med       Date:  2018-11-07

Review 4.  Insulin therapy for the treatment of type 1 diabetes during pregnancy.

Authors:  M James Lenhard; Brendan T Kinsley
Journal:  J Matern Fetal Neonatal Med       Date:  2013-12-12

Review 5.  Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital.

Authors:  Guillermo E Umpierrez; David C Klonoff
Journal:  Diabetes Care       Date:  2018-06-23       Impact factor: 19.112

Review 6.  Emerging Technologies for the Management of Type 1 Diabetes in Pregnancy.

Authors:  Jennifer M Yamamoto; Helen R Murphy
Journal:  Curr Diab Rep       Date:  2018-01-30       Impact factor: 4.810

7.  Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes.

Authors:  Aleksandra Jotic; Tanja Milicic; Katarina Lalic; Ljiljana Lukic; Marija Macesic; Jelena Stanarcic Gajovic; Milica Stoiljkovic; Miroslava Gojnic Dugalic; Veljko Jeremic; Nebojsa M Lalic
Journal:  Diabetes Ther       Date:  2020-02-15       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.